References
- Lamerz R, Reitheimer A, Stieber P, Eiermann W, Fateh Moghadam A. Role of blood markers in the detection of metastases from primary breast cancer. Diagn Oncol 1991; 1: 88–97
- Gion M. Serum markers in breast cancer management. Breast 1992; 1: 173–178
- van Dalen A. Tumour markers in breast cancer. Ann ChirGynaecol 1989; 78: 54–64
- Jäger W, Cilaci S, Merkle E, Palapelas V, Lang N. Analyse der Ersthinwiese auf eine Metastasierung bei Mammakarzinom-Patientinnen. Tumourdiagn u Ther 1991; 12: 60–64
- Geraghty J G, Coveney E C, Sherry F, O'Higgins N J, Duffy M J. CA 15—3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992; 70: 2831–2834
- Safi F, Köhler I, Rottinger E, Berg H G. The value of tumour marker CA 15—3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991; 68: 574–582
- Bonfrer JMG, Groeneveld E M, Korse C M, van Dalen A, Oomen LCJM, Ivanyi D. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantitation of tissue polypeptide antigen recognizes keratin 18. Tumour Biol 1994; 15: 210–222
- Nicolini A, Ferdeghini M, Colizzi C. Evaluation of CEA, TPA, CA 15—3, CA 549 and TPS in the monitoring of metastatic breast cancer. J Nucl Biol Med 1993; 37: 126–133
- van Dalen A, van der Linde D L, Heering K J, van BIusse Oud, Alblas A. How can treatment response be measured in breast cancer patients?. Anticancer Res 1993; 13: 1901–1904
- Ng JSY, Sturgeon C M, Seth J, Paterson G M, Roulston J E, Leonard RCF. Serological markers for metastatic breast cancer. Dis Markers 1993; 11: 1–7
- Gozdz S S, Kowalska M M, Sluszniak J T. Pretreatment concentrations of breast carcinoma antigen (CA 15.5) and mucin-like carcinoma-associated antigen in patients with carcinoma of the breast. Tumour Biol 1989; 10: 103–108
- Ruibal A, Colomer R, Genolla J. Prognostic value of CA 15—3 serum levels in patients having breast cancer. Horm Metab 1987; 1: 11–15
- van Dalen A. Re-oeprative tumour marker levels in patients with breast cancer and their prognosis. Tumour Biol 1990; 11: 189–195
- van Dalen A. Quality control and standardization of tumour marker tests. Tumour Biol 193;, 14: 131–135
- Gellenkeuser W J, Kruse R, Rohle G. Ringversuche der Deutschen Gesellschaft fur Klinische Chemie-Interpretation der Auswertung. DG Klinische Chemie Mitteilungen 1992; 23: 57–81
- Bonfrer JMG. Working group on tumour marker criteria (WGTMC). Tumour Biol 1990; 11: 287–288
- Gion M, Cappelli G, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli Gulisano R. Variability of tumour markers in the follow-up of patients radically resected for breast cancer. Tumour Biol 1993; 14: 325–333
- Hayward J L, Carbone P P, Heuson J C, Kumaoka S, Segaloff A, Rubens R D. Assessment of response to therapy in advanced breast cancer. Europ J Cancer 1977; 13: 88–94